Latin America Fabry Disease Treatment Market Size, Share, & Industry Analysis Report By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, By Country – Market Forecast, 2025–2034

The latin america fabry market size is expected to reach USD 164.68 million by 2034, according to a new study by Polaris Market Research. The report “Latin America Fabry Disease Treatment Market Size, Share, & Industry Analysis Report By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, By Country – Market Forecast, 2025–2034 – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The Latin America Fabry disease treatment market is witnessing steady growth, supported by an evolving healthcare landscape and increased prioritization of rare diseases in public health agendas. Growing awareness among clinicians and patients about the genetic nature and progressive symptoms of Fabry disease is leading to earlier diagnosis and more timely therapeutic interventions. Major urban centers across countries such as Brazil, Mexico, and Argentina are expanding their specialty care infrastructure, including the establishment of metabolic disorder clinics equipped to administer enzyme replacement therapy (ERT) and other advanced modalities. Industry analysis highlights a shift toward more personalized and accessible treatment models, with market expansion strategies increasingly focused on collaborations between regional healthcare providers and multinational pharmaceutical firms.

Strategic alliances and joint ventures are enabling the introduction of next-generation oral therapies, while improvements in distribution networks and pricing strategies are helping to broaden patient access. The region also presents opportunities for technology advancements, especially in telehealth and home-based treatment monitoring, which are expected to enhance adherence and outcomes in the coming years.

Latin America Fabry Disease Treatment Market Report Highlights

By route of administration, in 2024, the intravenous route segment was valued at USD 129 million and dominated the market revenue share due to its continued role as the primary method of delivering enzyme replacement therapy for Fabry disease.

Based on therapy, in 2024, the enzyme replacement therapy (ERT) segment was valued at approximately USD 135 million. The segment led the market revenue share driven by its established clinical efficacy and long-standing use in Fabry disease management.

The Brazil Fabry disease treatment market accounts for approximately 40% of the total regional revenue. The market growth is largely attributed to a combination of advanced healthcare access in major cities and government support for rare disease initiatives.

The Argentina Fabry disease treatment market is projected to register a CAGR of 6.5% from 2025 to 2034, fueled by a rising focus on rare disease detection and enhanced collaboration between public healthcare bodies and global pharmaceutical developers.

A few key players include Amicus Therapeutics, Inc.; CANbridge Life Sciences Ltd.; Chiesi Farmaceutici S.p.A.; Idorsia Pharmaceuticals Ltd.; ISU ABXIS Co., Ltd.; JCR Pharmaceuticals Co., Ltd.; Protalix Biotherapeutics Inc.; Sangamo Therapeutics, Inc.; Sanofi; and Takeda Pharmaceutical.

Polaris Market Research has segmented the Latin America Fabry disease treatment market report on the basis of route of administration, therapy, distribution channel, and country:

By Route of Administration Outlook (Revenue USD Million, 2020–2034)

Intravenous Route

Oral Route

By Therapy Outlook (Revenue USD Million, 2020–2034)

Enzyme Replacement Therapy (ERT)

Substrate Reduction Therapy (SRT)

Others

By Distribution Channel Outlook (Revenue USD Million, 2020–2034)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Country Outlook (Revenue USD Million, 2020–2034)

Brazil

Mexico

Argentina

Colombia

Chile

Peru

Ecuador

Paraguay

Rest of LATAM